Capricor partners with Nippon Shinyaku for CAP-1002 in Japan; $12M upfront, up to $89M milestones

CAPRICOR THERAPEUTICS, INC.

Exclusive Japan commercialization and distribution agreement for CAP-1002 in Duchenne muscular dystrophy.
Capricor receives $12M upfront plus up to ~$89M in development and sales milestones.
Capricor also gets a meaningful double-digit percentage of product revenue from Japan sales.
Capricor retains marketing authorization and clinical development; Nippon Shinyaku handles distribution.
Follows a similar U.S. deal with Nippon Shinyaku signed in January 2022.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. entered into Japan Agreement with Nippon Shinyaku, Co., Ltd. valued at upfront payment of $12 million and ... additional development and sales-based milestone payments of (effective 2023-02-10).

Action: entry
Agreement: supply
Counterparty: Nippon Shinyaku, Co., Ltd.
Value: upfront payment of $12 million and ... additional development and sales-based milestone payments of
Effective: 2023-02-10

Exact text from the filing

Capricor Therapeutics, Inc. (the “Company” or “Capricor”) entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Agreement”) with Nippon Shinyaku, Co., Ltd., a Japanese corporation, (“Nippon Shinyaku”) effective February 10, 2023.

View on SEC.gov

631 material agreements filed in the last 30 days. Browse all material agreements →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-001454

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.